JP2010528000A - 濃縮エスモロール - Google Patents
濃縮エスモロール Download PDFInfo
- Publication number
- JP2010528000A JP2010528000A JP2010509320A JP2010509320A JP2010528000A JP 2010528000 A JP2010528000 A JP 2010528000A JP 2010509320 A JP2010509320 A JP 2010509320A JP 2010509320 A JP2010509320 A JP 2010509320A JP 2010528000 A JP2010528000 A JP 2010528000A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- esmolol
- acetic acid
- glacial acetic
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Abstract
Description
本発明の一態様では、濃縮エスモロール製剤が提供される。濃縮エスモロール製剤は、約40〜60mg/mlのエスモロール(または薬学的に許容されるその塩)、さらに場合により約0.005〜約2モル濃度(M)の緩衝剤を含有し、約3.5〜約7.0の間にpH調整されている。
本発明の組成物は、エスモロールまたは薬学的に許容されるその塩、例えば塩酸塩、緩衝剤、さらに場合により浸透圧調整剤を含む。本明細書では、「エスモロール」は、エスモロール遊離塩基および薬学的に許容されるその塩を指す。この溶液は、無菌であり、好ましくは、適切な容器に詰められ、高圧蒸気滅菌によって最終滅菌される。あるいは、無菌エスモロール濃縮物は、無菌充填手順によって調製することもできる。濃縮物中のエスモロールの濃度は、約40〜60mg/mlの範囲に及び、好ましくは約45〜55mg/ml、最も好ましくは50mg/mlである。
以下で、本発明のエスモロール組成物の調製について述べる。組成物の各成分の濃度を以下のとおり表1および2に示す。
Claims (34)
- a)約40〜60mg/mlのエスモロール塩酸塩と、
b)約0.01〜約2Mの緩衝剤と
を含み、pHが約4.0〜6.0である、濃縮されたエスモロール組成物。 - 前記緩衝剤が、酢酸塩、グルタミン酸塩、クエン酸塩、酒石酸塩、安息香酸塩、乳酸塩、グルコン酸塩、リン酸塩、およびグリシン、ならびにこれらの共役酸のうち少なくとも1種を含む、請求項1に記載の組成物。
- 前記緩衝剤が酢酸ナトリウムおよび酢酸を含む、請求項2に記載の組成物。
- 浸透圧調整剤をさらに含む、請求項1に記載の組成物。
- 前記浸透圧調整剤が、デキストロース、塩化ナトリウム、炭酸水素ナトリウム、塩化カルシウム、塩化カリウム、乳酸ナトリウム、およびリンガー液からなる群から選択される、請求項4に記載の組成物。
- 前記浸透圧調整剤が約0.1〜約5mg/mlの量で存在する、請求項4に記載の組成物。
- a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの氷酢酸、および
c)約1mg/mlの塩化ナトリウム
を含む、請求項4に記載の組成物。 - a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項4に記載の組成物。 - a)約45〜55mg/mlのエスモロールHCl、
b)約0.005Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項4に記載の組成物。 - a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlのデキストロース
を含む、請求項4に記載の組成物。 - a)約45〜55mg/mlのエスモロールHCl、
b)約0.02Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項4に記載の組成物。 - a)約45〜55mg/mlのエスモロールHCl、
b)約0.02Mの酢酸ナトリウム、および
c)約0.01Mの氷酢酸
を含む、請求項1に記載の組成物。 - a)容器に収容された約40〜約60mg/mlのエスモロール塩酸塩と約0.01〜約2Mの緩衝剤とを含む組成物と、
b)実施者に、該組成物を直接注射に使用するように、または希釈してから注射に使用するように指示する説明書と、
c)該容器および説明書を収容する包装と
を含む医療用製品。 - 前記緩衝剤が、酢酸塩、グルタミン酸塩、クエン酸塩、酒石酸塩、安息香酸塩、乳酸塩、グルコン酸塩、リン酸塩、およびグリシン、ならびにこれらの共役酸のうち少なくとも1種を含む、請求項13に記載の医療用製品。
- 前記緩衝剤が酢酸ナトリウムおよび酢酸を含む、請求項13に記載の医療用製品。
- 濃縮エスモロール製剤が浸透圧調整剤をさらに含む、請求項13に記載の医療用製品。
- 前記組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの氷酢酸、および
c)約1mg/mlの塩化ナトリウム
を含む、請求項16に記載の方法。 - 前記組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項16に記載の方法。 - 前記組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.005Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項16に記載の方法。 - 前記組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlのデキストロース
を含む、請求項16に記載の方法。 - 前記組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.02Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項16に記載の方法。 - 前記組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.02Mの酢酸ナトリウム、および
c)約0.01Mの氷酢酸
を含む、請求項13に記載の方法。 - エスモロール濃縮液体組成物が不適切に投薬された結果として生じる実質的な健康への悪影響の潜在的可能性を軽減する方法であって、該方法は、
a)約40〜60mg/mlのエスモロール塩酸塩と、
b)約0.01〜約2Mの緩衝剤とを含む無菌液体組成物を準備するステップ
を含み、該組成物のpHが約4.0〜6.0である、方法。 - 前記緩衝剤が、酢酸塩、グルタミン酸塩、クエン酸塩、酒石酸塩、安息香酸塩、乳酸塩、グルコン酸塩、リン酸塩、およびグリシン、ならびにこれらの共役酸のうち少なくとも1種を含む、請求項23に記載の方法。
- 前記緩衝剤が酢酸ナトリウムおよび酢酸を含む、請求項23に記載の方法。
- 浸透圧調整剤をさらに含む、請求項23に記載の方法。
- 前記浸透圧調整剤が、デキストロース、塩化ナトリウム、炭酸水素ナトリウム、塩化カルシウム、塩化カリウム、乳酸ナトリウム、およびリンガー液からなる群から選択される、請求項23に記載の方法。
- 前記浸透圧調整剤が約0.1〜約5mg/mlの量で存在する、請求項23に記載の方法。
- 無菌液体組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの氷酢酸、および
c)約1mg/mlの塩化ナトリウム
を含む、請求項27に記載の方法。 - 無菌液体組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項27に記載の方法。 - 無菌液体組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.005Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項27に記載の方法。 - 無菌液体組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.01Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlのデキストロース
を含む、請求項27に記載の方法。 - 無菌液体組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.02Mの酢酸ナトリウム、
c)約0.01Mの氷酢酸、および
d)約1mg/mlの塩化ナトリウム
を含む、請求項27に記載の方法。 - 無菌液体組成物が、
a)約45〜55mg/mlのエスモロールHCl、
b)約0.02Mの酢酸ナトリウム、および
c)約0.01Mの氷酢酸
を含む、請求項23に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/752,037 US20080293814A1 (en) | 2007-05-22 | 2007-05-22 | Concentrate esmolol |
US11/752,037 | 2007-05-22 | ||
PCT/US2007/074325 WO2008153582A1 (en) | 2007-05-22 | 2007-07-25 | Concentrate esmolol |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010528000A true JP2010528000A (ja) | 2010-08-19 |
JP5759720B2 JP5759720B2 (ja) | 2015-08-05 |
Family
ID=39811512
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010509320A Expired - Fee Related JP5759720B2 (ja) | 2007-05-22 | 2007-07-25 | 濃縮エスモロール |
Country Status (14)
Country | Link |
---|---|
US (2) | US20080293814A1 (ja) |
EP (1) | EP2164463A1 (ja) |
JP (1) | JP5759720B2 (ja) |
KR (1) | KR20100022068A (ja) |
CN (1) | CN101674803A (ja) |
AR (1) | AR066670A1 (ja) |
AU (1) | AU2007354870A1 (ja) |
BR (1) | BRPI0721680A2 (ja) |
CA (1) | CA2686548A1 (ja) |
IL (1) | IL201985A0 (ja) |
MX (1) | MX344131B (ja) |
RU (1) | RU2493824C2 (ja) |
WO (1) | WO2008153582A1 (ja) |
ZA (1) | ZA200908756B (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018080154A (ja) * | 2016-11-16 | 2018-05-24 | 光製薬株式会社 | パロノセトロンを含有する安定な注射用液剤の製造方法 |
JP2022513346A (ja) * | 2020-02-18 | 2022-02-07 | ノヴォ ノルディスク アー/エス | Glp-1組成物およびその使用 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2011039780A2 (en) * | 2009-09-22 | 2011-04-07 | Vlife Sciences Technologies Pvt. Ltd. | Topical formulation for diabetic foot ulcers |
BR112013018598A2 (pt) * | 2011-01-27 | 2016-10-18 | Baxter Healthcare Sa | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca |
CA2825311A1 (en) * | 2011-01-27 | 2012-08-02 | Baxter International Inc. | Methods of treating tachycardia and/or controlling heart rate while minimizing and/or controlling hypotension |
MY173900A (en) | 2012-05-10 | 2020-02-26 | Aop Orphan Pharmaceuticals Ag | Parenteral esmolol formulation |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54105221A (en) * | 1978-02-02 | 1979-08-18 | Sankyo Co Ltd | Preparation of stable concentrated dopa injection |
JPH03500658A (ja) * | 1988-06-08 | 1991-02-14 | イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー(インコーポレイテツド) | 安定な医薬組成物 |
JPH09208465A (ja) * | 1996-02-07 | 1997-08-12 | Takeda Chem Ind Ltd | 高濃度注射用モルヒネ液 |
JP2004519506A (ja) * | 2001-01-12 | 2004-07-02 | バクスター・インターナショナル・インコーポレイテッド | エスモロール処方物 |
JP2006257020A (ja) * | 2005-03-17 | 2006-09-28 | Towa Yakuhin Kk | 安定な高濃度エダラボン注射液 |
Family Cites Families (93)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2745785A (en) * | 1952-10-29 | 1956-05-15 | American Home Prod | Therapeutic composition comprising tabular nu, nu'-dibenzylethylenediamine di-penicillin, and process for preparing same |
GB1472793A (en) * | 1974-03-28 | 1977-05-04 | Ici Ltd | Pharmaceutical compositions |
US4798846A (en) * | 1974-03-28 | 1989-01-17 | Imperial Chemical Industries Plc | Pharmaceutical compositions |
US4073943A (en) * | 1974-09-11 | 1978-02-14 | Apoteksvarucentralen Vitrum Ab | Method of enhancing the administration of pharmalogically active agents |
US4593119A (en) * | 1980-11-28 | 1986-06-03 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
US4387103A (en) * | 1980-11-28 | 1983-06-07 | American Hospital Supply Corporation | Method for treatment or prophylaxis of cardiac disorders |
US4725442A (en) * | 1983-06-17 | 1988-02-16 | Haynes Duncan H | Microdroplets of water-insoluble drugs and injectable formulations containing same |
WO1985004580A1 (en) * | 1984-04-09 | 1985-10-24 | American Hospital Supply Corporation | Pharmaceutical composition and method for treatment or prophylaxis of cardiac disorders |
US4826689A (en) * | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US5023271A (en) * | 1985-08-13 | 1991-06-11 | California Biotechnology Inc. | Pharmaceutical microemulsions |
FR2608988B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
IL86211A (en) * | 1987-05-04 | 1992-03-29 | Ciba Geigy Ag | Oral forms of administration for carbamazepine in the forms of stable aqueous suspension with delayed release and their preparation |
US5707634A (en) * | 1988-10-05 | 1998-01-13 | Pharmacia & Upjohn Company | Finely divided solid crystalline powders via precipitation into an anti-solvent |
FR2651680B1 (fr) * | 1989-09-14 | 1991-12-27 | Medgenix Group Sa | Nouveau procede de preparation de microparticules lipidiques. |
US5188837A (en) * | 1989-11-13 | 1993-02-23 | Nova Pharmaceutical Corporation | Lipsopheres for controlled delivery of substances |
US5078994A (en) * | 1990-04-12 | 1992-01-07 | Eastman Kodak Company | Microgel drug delivery system |
US5091188A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
US5091187A (en) * | 1990-04-26 | 1992-02-25 | Haynes Duncan H | Phospholipid-coated microcrystals: injectable formulations of water-insoluble drugs |
JP3282731B2 (ja) * | 1990-06-15 | 2002-05-20 | メルク エンド カムパニー インコーポレーテッド | 結晶の構造および大きさを改良する結晶化方法 |
US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
AU642066B2 (en) * | 1991-01-25 | 1993-10-07 | Nanosystems L.L.C. | X-ray contrast compositions useful in medical imaging |
US5306519A (en) * | 1991-05-23 | 1994-04-26 | Universal Foods Corporation | Syrup for confections and methods for using same |
CH683149A5 (fr) * | 1991-07-22 | 1994-01-31 | Debio Rech Pharma Sa | Procédé pour la préparation de microsphères en matériau polymère biodégradable. |
US6063910A (en) * | 1991-11-14 | 2000-05-16 | The Trustees Of Princeton University | Preparation of protein microparticles by supercritical fluid precipitation |
US5389263A (en) * | 1992-05-20 | 1995-02-14 | Phasex Corporation | Gas anti-solvent recrystallization and application for the separation and subsequent processing of RDX and HMX |
US5417956A (en) * | 1992-08-18 | 1995-05-23 | Worcester Polytechnic Institute | Preparation of nanophase solid state materials |
NZ248813A (en) * | 1992-11-25 | 1995-06-27 | Eastman Kodak Co | Polymeric grinding media used in grinding pharmaceutical substances |
US5298262A (en) * | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5302401A (en) * | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
DE4305003A1 (de) * | 1993-02-18 | 1994-08-25 | Knoll Ag | Verfahren zur Herstellung kolloidaler wäßriger Lösungen schwer löslicher Wirkstoffe |
US5885486A (en) * | 1993-03-05 | 1999-03-23 | Pharmaciaand Upjohn Ab | Solid lipid particles, particles of bioactive agents and methods for the manufacture and use thereof |
FR2703927B1 (fr) * | 1993-04-13 | 1995-07-13 | Coletica | Utilisation d'une réaction de transacylation entre un polysaccharide estérifié et une polyamine pour former en milieu aqueux une membrane au moins en surface de particules gélifiées. |
DE69429524T2 (de) * | 1993-09-24 | 2002-08-08 | Univ British Columbia | Aminocyclohexylester und ihre anwendung |
TW384224B (en) * | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
GB9413202D0 (en) * | 1994-06-30 | 1994-08-24 | Univ Bradford | Method and apparatus for the formation of particles |
WO1996009840A1 (en) * | 1994-09-27 | 1996-04-04 | Nycomed Imaging A/S | Contrast agent |
US5720551A (en) * | 1994-10-28 | 1998-02-24 | Shechter; Tal | Forming emulsions |
DE4440337A1 (de) * | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
US5716642A (en) * | 1995-01-10 | 1998-02-10 | Nano Systems L.L.C. | Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents |
US5518738A (en) * | 1995-02-09 | 1996-05-21 | Nanosystem L.L.C. | Nanoparticulate nsaid compositions |
US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5605785A (en) * | 1995-03-28 | 1997-02-25 | Eastman Kodak Company | Annealing processes for nanocrystallization of amorphous dispersions |
ATE212545T1 (de) * | 1995-03-28 | 2002-02-15 | Fidia Advanced Biopolymers Srl | Nanosphären mit einem biokompatiblen polysaccharid |
SE9501384D0 (sv) * | 1995-04-13 | 1995-04-13 | Astra Ab | Process for the preparation of respirable particles |
US6143211A (en) * | 1995-07-21 | 2000-11-07 | Brown University Foundation | Process for preparing microparticles through phase inversion phenomena |
CA2253260A1 (en) * | 1996-05-02 | 1997-11-13 | Taisho Pharmaceutical Co., Ltd. | Suspension of sparingly water-soluble acidic drug |
CZ299790B6 (cs) * | 1996-08-22 | 2008-11-26 | Skyepharma Canada Inc. | Kompozice mikrocástic ve vode nerozpustné látky, farmaceutická kompozice, zpusob prípravy stabilních cástic, mikrocástice ve vode nerozpustné nebo slabe rozpustné slouceniny, kompozice obsahující tyto mikrocástice a zpusob prípravy mikrocástic |
US6344271B1 (en) * | 1998-11-06 | 2002-02-05 | Nanoenergy Corporation | Materials and products using nanostructured non-stoichiometric substances |
AU4807197A (en) * | 1996-10-03 | 1998-04-24 | Paul Bunn | Hydrophilic microparticles and methods to prepare same |
CA2275317A1 (en) * | 1996-12-17 | 1998-06-25 | H. Eugene Johnston | Salting-out process of crystallizing 2,4,6,8,10,12-hexanitro-2,4,6,8,10,12-hexaazatetracyclo¬5.5.0.05,903,11|-dodecane |
US5874111A (en) * | 1997-01-07 | 1999-02-23 | Maitra; Amarnath | Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles |
US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
IT1292142B1 (it) * | 1997-06-12 | 1999-01-25 | Maria Rosa Gasco | Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale |
KR19990001564A (ko) * | 1997-06-16 | 1999-01-15 | 유충식 | 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제 |
US6217886B1 (en) * | 1997-07-14 | 2001-04-17 | The Board Of Trustees Of The University Of Illinois | Materials and methods for making improved micelle compositions |
US6159442A (en) * | 1997-08-05 | 2000-12-12 | Mfic Corporation | Use of multiple stream high pressure mixer/reactor |
US6281175B1 (en) * | 1997-09-23 | 2001-08-28 | Scimed Life Systems, Inc. | Medical emulsion for lubrication and delivery of drugs |
US5886239A (en) * | 1997-11-21 | 1999-03-23 | Baxter International Inc. | Method of preparing monofluoromethyl ethers |
US6337092B1 (en) * | 1998-03-30 | 2002-01-08 | Rtp Pharma Inc. | Composition and method of preparing microparticles of water-insoluble substances |
CA2326456C (en) * | 1998-03-30 | 2008-12-23 | Rtp Pharma Inc. | Composition and method of preparing microparticles of water-insoluble substances |
AU755993C (en) * | 1998-06-19 | 2003-10-30 | Skyepharma Canada Inc. | Processes to generate submicron particles of water-insoluble compounds |
FR2780901B1 (fr) * | 1998-07-09 | 2000-09-29 | Coletica | Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant |
US6238677B1 (en) * | 1998-08-18 | 2001-05-29 | The United States Of America As Represented By The Secretary Of Agriculture | Starch microcapsules for delivery of active agents |
US8293277B2 (en) * | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US6365191B1 (en) * | 1999-02-17 | 2002-04-02 | Dabur Research Foundation | Formulations of paclitaxel, its derivatives or its analogs entrapped into nanoparticles of polymeric micelles, process for preparing same and the use thereof |
US6045826A (en) * | 1999-04-02 | 2000-04-04 | National Research Council Of Canada | Water-soluble compositions of bioactive lipophilic compounds |
US6610317B2 (en) * | 1999-05-27 | 2003-08-26 | Acusphere, Inc. | Porous paclitaxel matrices and methods of manufacture thereof |
US6395300B1 (en) * | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
KR100331529B1 (ko) * | 1999-06-16 | 2002-04-06 | 민경윤 | 난용성 항진균제의 경구투여용 조성물 및 그의 제조 방법 |
NZ519984A (en) * | 2000-01-07 | 2004-03-26 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
AU2001257115B2 (en) * | 2000-04-20 | 2005-01-27 | Rtp Pharma Inc. | Improved water-insoluble drug particle process |
JP3412606B2 (ja) * | 2000-08-04 | 2003-06-03 | 株式会社島津製作所 | レーザ回折・散乱式粒度分布測定装置 |
DE60140625D1 (de) * | 2000-08-15 | 2010-01-07 | Univ Illinois | Verfahren zur herstellung von mikropartikeln |
ES2326209T3 (es) * | 2000-10-27 | 2009-10-05 | Baxter Healthcare S.A. | Produccion de microesferas. |
DE10063712C1 (de) * | 2000-12-20 | 2002-08-29 | Stiftung A Wegener Inst Polar | Mikrobiologisches Verfahren zur Biosynthese der natürlichen blau-violetten Farbstoffe Violacein und Desoxyviolacein und deren Verwendung |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US7037528B2 (en) * | 2000-12-22 | 2006-05-02 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US6977085B2 (en) * | 2000-12-22 | 2005-12-20 | Baxter International Inc. | Method for preparing submicron suspensions with polymorph control |
US6951656B2 (en) * | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US20030096013A1 (en) * | 2000-12-22 | 2003-05-22 | Jane Werling | Preparation of submicron sized particles with polymorph control |
US20030072807A1 (en) * | 2000-12-22 | 2003-04-17 | Wong Joseph Chung-Tak | Solid particulate antifungal compositions for pharmaceutical use |
US7193084B2 (en) * | 2000-12-22 | 2007-03-20 | Baxter International Inc. | Polymorphic form of itraconazole |
US20040022862A1 (en) * | 2000-12-22 | 2004-02-05 | Kipp James E. | Method for preparing small particles |
US6310094B1 (en) * | 2001-01-12 | 2001-10-30 | Baxter International Inc. | Ready-to-use esmolol solution |
US20040022861A1 (en) * | 2001-01-30 | 2004-02-05 | Williams Robert O. | Process for production of nanoparticles and microparticles by spray freezing into liquid |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
MXPA04002446A (es) * | 2001-09-26 | 2004-07-23 | Baxter Int | Preparacion de nanoparticulas de tamano de submicras mediante dispersion y remocion de la fase liquida o solvente. |
US20060003012A9 (en) * | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
US7112340B2 (en) * | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
EP1417962A1 (de) * | 2002-11-06 | 2004-05-12 | AOP Orphan Pharmaceuticals AG | Verfahren zur Herstellung eines Arzneimittels enthaltend Esmolol |
-
2007
- 2007-05-22 US US11/752,037 patent/US20080293814A1/en not_active Abandoned
- 2007-07-25 WO PCT/US2007/074325 patent/WO2008153582A1/en active Application Filing
- 2007-07-25 EP EP07840511A patent/EP2164463A1/en not_active Withdrawn
- 2007-07-25 MX MX2009012616A patent/MX344131B/es active IP Right Grant
- 2007-07-25 RU RU2009147458/15A patent/RU2493824C2/ru not_active IP Right Cessation
- 2007-07-25 KR KR1020097026610A patent/KR20100022068A/ko not_active Application Discontinuation
- 2007-07-25 CN CN200780053072A patent/CN101674803A/zh active Pending
- 2007-07-25 AU AU2007354870A patent/AU2007354870A1/en not_active Abandoned
- 2007-07-25 JP JP2010509320A patent/JP5759720B2/ja not_active Expired - Fee Related
- 2007-07-25 BR BRPI0721680-7A patent/BRPI0721680A2/pt not_active IP Right Cessation
- 2007-07-25 CA CA002686548A patent/CA2686548A1/en not_active Abandoned
-
2008
- 2008-05-21 AR ARP080102161A patent/AR066670A1/es not_active Application Discontinuation
-
2009
- 2009-11-08 IL IL201985A patent/IL201985A0/en unknown
- 2009-12-09 ZA ZA200908756A patent/ZA200908756B/xx unknown
-
2014
- 2014-09-12 US US14/485,632 patent/US20150005376A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54105221A (en) * | 1978-02-02 | 1979-08-18 | Sankyo Co Ltd | Preparation of stable concentrated dopa injection |
JPH03500658A (ja) * | 1988-06-08 | 1991-02-14 | イー・アイ・デユポン・ド・ネモアース・アンド・コンパニー(インコーポレイテツド) | 安定な医薬組成物 |
JPH09208465A (ja) * | 1996-02-07 | 1997-08-12 | Takeda Chem Ind Ltd | 高濃度注射用モルヒネ液 |
JP2004519506A (ja) * | 2001-01-12 | 2004-07-02 | バクスター・インターナショナル・インコーポレイテッド | エスモロール処方物 |
JP2006257020A (ja) * | 2005-03-17 | 2006-09-28 | Towa Yakuhin Kk | 安定な高濃度エダラボン注射液 |
Non-Patent Citations (1)
Title |
---|
JPN6013022197; 尾鳥勝也ら: Prog. Med. Vol.22, 2002, p.1047-1054 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2018080154A (ja) * | 2016-11-16 | 2018-05-24 | 光製薬株式会社 | パロノセトロンを含有する安定な注射用液剤の製造方法 |
JP2022513346A (ja) * | 2020-02-18 | 2022-02-07 | ノヴォ ノルディスク アー/エス | Glp-1組成物およびその使用 |
US11318191B2 (en) | 2020-02-18 | 2022-05-03 | Novo Nordisk A/S | GLP-1 compositions and uses thereof |
JP7132441B2 (ja) | 2020-02-18 | 2022-09-06 | ノヴォ ノルディスク アー/エス | Glp-1組成物およびその使用 |
Also Published As
Publication number | Publication date |
---|---|
WO2008153582A1 (en) | 2008-12-18 |
ZA200908756B (en) | 2010-08-25 |
CA2686548A1 (en) | 2008-12-18 |
MX2009012616A (es) | 2009-12-11 |
CN101674803A (zh) | 2010-03-17 |
BRPI0721680A2 (pt) | 2014-02-25 |
RU2009147458A (ru) | 2011-06-27 |
AR066670A1 (es) | 2009-09-02 |
AU2007354870A1 (en) | 2008-12-18 |
JP5759720B2 (ja) | 2015-08-05 |
MX344131B (es) | 2016-12-06 |
EP2164463A1 (en) | 2010-03-24 |
US20150005376A1 (en) | 2015-01-01 |
US20080293814A1 (en) | 2008-11-27 |
KR20100022068A (ko) | 2010-02-26 |
RU2493824C2 (ru) | 2013-09-27 |
IL201985A0 (en) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5778384B2 (ja) | エスモロール処方物 | |
JP5759720B2 (ja) | 濃縮エスモロール | |
ES2272720T3 (es) | Formulacion de esmolol. | |
JP5825785B2 (ja) | 着色されたエスモロール濃縮物 | |
AU2008256949B2 (en) | Multi-dose concentrate esmolol with benzyl alcohol | |
EP2846776B1 (en) | Parenteral esmolol formulation | |
AU2014203121B2 (en) | Concentrate esmolol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100726 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110713 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130128 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130510 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130906 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130918 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141008 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141014 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141107 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141112 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20141208 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20141211 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150311 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150608 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5759720 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |